Integrating the Quit and Stay Quit Monday Model Into Smoking Cessation Services for Smokers With Mental Health Conditions
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04512248 |
Recruitment Status :
Completed
First Posted : August 13, 2020
Last Update Posted : January 5, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Smoking Cessation | Behavioral: Quit and Stay Quit Monday Model | Not Applicable |
The overall objective of this proposal is to innovate the tobacco treatment paradigm for smokers with mental health conditions (MHC) by integrating the Quit and Stay Quit Monday Model into smoking cessation services for this vulnerable population.
The investigator will conduct a two-group, parallel-randomized controlled trial (RCT). The target population will be generated by the NYU Langone electronic medical record (EMR). The investigator will proactively contact patients to offer enrollment and randomize participants 1:1 to one of two groups (n=50/group): (1) Quit and Stay Quit Monday Model or (2) Usual Care. For evaluation, phone surveys will be conducted at baseline and 3-months to assess quit attempts, intervention satisfaction, and smoking cessation.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 70 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Two-group, parallel-randomized controlled trial |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Integrating the Quit and Stay Quit Monday Model Into Smoking Cessation Services for Smokers With Mental Health Conditions |
Actual Study Start Date : | October 1, 2020 |
Actual Primary Completion Date : | October 30, 2021 |
Actual Study Completion Date : | October 30, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Quit and Stay Quit Monday Model |
Behavioral: Quit and Stay Quit Monday Model
Participants randomized to the study intervention will receive: (1) 2 telephone smoking cessation coaching calls; (2) enrollment into SmokefreeTXT; and (3) enrollment in the iquitmonday.org weekly email newsletter. The telephone coaches will ask these participants to identify a future Monday as their quit date and provide coaching to achieve a Monday quit. The coaches will also enter the selected Monday as the patient's quit day when enrolling the patient into SmokefreeTXT. |
No Intervention: Usual Care |
- Incidence of 3-month quit attempts [ Time Frame: 3 months ]Phone surveys will be conducted to obtain information
- Incidence of smoking cessation [ Time Frame: 3 months ]Phone surveys will be conducted to obtain information
- Number of participants who report satisfaction in intervention [ Time Frame: 3 months ]Phone surveys will be conducted to obtain information

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age ≥ 18 years old
- Has smoked a cigarette in the past 30 days, even a puff
- Has been diagnosed with a mental health condition or received care from a mental health clinic within the NYU Langone Health system in the prior 12 months
- Interested in quitting smoking
- English language
- Has a phone that can receive text messages
- Able to provide informed consent
Exclusion Criteria:
- age < 18 years of age
- Non-smoker

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04512248
United States, New York | |
NYU Langone Health | |
New York, New York, United States, 10016 |
Principal Investigator: | Erin Rogers, DrPH | NYU Langone Health |
Responsible Party: | NYU Langone Health |
ClinicalTrials.gov Identifier: | NCT04512248 |
Other Study ID Numbers: |
20-01247 |
First Posted: | August 13, 2020 Key Record Dates |
Last Update Posted: | January 5, 2022 |
Last Verified: | December 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) |
Time Frame: | Data will become available beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research. |
Access Criteria: | The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to ERIN.ROGERS@NYULANGONE.ORG. To gain access, data requestors will need to sign a data access agreement. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |